Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI
Active, not recruiting · NCT06811805 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Post-Marketing Study to Assess the Safety & Efficacy of RenalGuard® Therapy for Prevention CSA-AKI | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, acute kidney injury, kidney disorder, kidney failure, urinary system disorder | Active, not recruiting | Not applicable | 2026-01-23 | NCT06811805 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CardioRenal Systems, Inc. | 2 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hospital de la Santa Creu i Sant Pau | Barcelona | Spain | 64 |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | 42 |
| Jessa Medica Center | Hasselt | Belgium | 1 |
| Rabin Medical Center - Belinson Campus | Petah Tikva | Israel | 2 |
| Rambam Medical Center | Haifa | Israel | 19 |
| Sahlgrenska University Hospital | Gothenburg | Sweden | 96 |
| TUM Klinikum Deutsches Herzzentrum | Munich | Germany | 1 |
| Uniklinikum Munster | Münster | Germany | 1 |